Biotechnology firm Biocytogen Pharmaceuticals (HKEX: 02315) announced on Monday that biotechnology company Adcendo ApS has exercised its option to leverage Biocytogen's fully human antibodies under a licensing agreement.

This move aims to accelerate the development of Adcendo's antibody-drug conjugate (ADC) pipeline, targeting cancers with significant unmet medical needs.

The partnership highlights the capabilities of Biocytogen's RenMice antibody discovery platform, designed for generating fully human monoclonal, bispecific, and multispecific antibodies. Biocytogen has established a robust global presence, collaborating with multinational pharmaceutical companies and supporting over 150 therapeutic antibody projects.

Adcendo focuses on first-in-class ADCs, employing Biocytogen's proprietary technology to enhance its development of innovative oncology therapies. This collaboration underscores Biocytogen's role as a leader in advancing novel therapeutic solutions through cutting-edge biotechnology.